DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This application is a domestic application, filed 19 July 2024; and claims benefit as a CON of 17/295,090, which is a 371 of PCT/US2019/062192 filed 19 Nov 2019, issued as PAT 12,091,471; which claims benefit of provisional application 62/769,161, filed 19 Nov 2018.
Claims 106-125 are pending in the current application and are examined on the merits herein.
Double Patenting - Statutory
A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957).
A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.
Claim 106 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 13 of prior U.S. Patent No. 12,091,471. This is a statutory double patenting rejection.
Reference Claim 13 of the Reference patent recites “A hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an organic acid solution prior to acrylation, the hydrogel composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after combination of the oxidized dextran with the acrylated chitosan composition,” and “wherein, when formed with a thickness of 2 mm to 10 mm, is substantially transparent.” (emphasis added)
Examined claim 106 recites “A biodegradable hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an organic acid solution prior to acrylation, the biodegradable composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after combination of the oxidized dextran with the acrylated chitosan composition and when formed with a thickness of 2 mm to 10 mm is substantially transparent.” (emphasis added)
MPEP 2112.01 especially at I. citing In re Best, 562 F.2d 1252, 195 USPQ 430 (C.C.P.A. 1977) and In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) discusses the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly recited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to show the products of the applicant and the prior art are not the same or that the prior art products do not necessarily possess the characteristics of the claimed product. While the Reference claim 13 and examined claim 106 differ in the descriptor for the hydrogel composition, “hemostatic” vs. “biodegradable” respectively, both hydrogel compositions comprise identical chemical components characterized by identical physical properties. Therefore there is reason to believe that the claimed inventions are drawn to identical subject matter, and the functions of being “hemostatic” and “biodegradable” are necessarily present in both claimed inventions.
Claim 116 is rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 16 of prior U.S. Patent No. 12,091,471. This is a statutory double patenting rejection.
Reference Claim 16 of the Reference patent recites “A hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an acetic acid solution prior to acrylation, the hydrogel composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after formation” and “wherein the hemostatic hydrogel composition is substantially transparent when the hydrogel composition has a thickness of 2 mm to 10 mm.” (emphasis added)
Examined claim 116 recites “A biodegradable hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an organic acid solution prior to acrylation, the biodegradable composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after combination of the oxidized dextran with the acrylated chitosan composition and when formed with a thickness of 2 mm to 10 mm is substantially transparent” and “wherein the organic acid is acetic acid.” (emphasis added)
MPEP 2112.01 especially at I. citing In re Best, 562 F.2d 1252, 195 USPQ 430 (C.C.P.A. 1977) and In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) discusses the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly recited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to show the products of the applicant and the prior art are not the same or that the prior art products do not necessarily possess the characteristics of the claimed product. While the Reference claim 16 and examined claim 116 differ in the descriptor for the hydrogel composition, “hemostatic” vs. “biodegradable” respectively, both hydrogel compositions comprise identical chemical components characterized by identical physical properties. Therefore there is reason to believe that the claimed inventions are drawn to identical subject matter, and the functions of being “hemostatic” and “biodegradable” are necessarily present in both claimed inventions.
Double Patenting – Non-Statutory
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 106-125 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 12,091,471.
Although the claims at issue are not identical, they are not patentably distinct from each other because Reference claims 1-7 and 11-30 are drawn to a hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an organic acid solution prior to acrylation. Reference Claim 13 recites the hemostatic hydrogel wherein, when formed with a thickness of 2 mm to 10 mm, is substantially transparent, addressing limitations of claim 106. Reference claim 11 recites the hydrogel composition further comprises one or more features including the alternatives (ix) at about 10 seconds after combining the oxidized dextran with the acrylated chitosan composition, the hemostatic hydrogel composition has a burst strength of greater than 20 mmHg as determined using an ASTM F 2392-04 protocol, (x) at about 2 minutes after combining the oxidized dextran with the acrylated chitosan composition, the hemostatic hydrogel composition has a burst strength of greater than about 35 mmHg as determined using an ASTM F 2392-04 protocol, and (xi) an elastic modulus of from about 500 Pa to about 5000 Pa at from about 10 seconds to about 80 seconds after combining the oxidized dextran with the acrylated chitosan composition, addressing limitations of claim 107-109. Reference claim 5 recites the hydrogel composition comprising specific mole fractions of formulas (I), (III), and (V), addressing limitations of claim 110. Reference claim 6 recites specific mole fractions of formula (IV), addressing limitations of claim 111. Reference claim 6 recites specific mole fractions of formula (VIII), addressing limitations of claim 112. Reference claim 12 recites the hydrogel composition wherein, when formed, has a volume that does not increase upon exposure to a physiological fluid or body fluid, addressing limitations of claim 113. Reference claim 14 recites the hemostatic hydrogel composition wherein, when formed, has a volume that shrinks by less than about 5% about 10 minutes after formation when exposed to a physiological fluid or body fluid, addressing limitations of claim 114. Reference claim 15 corresponds to the limitations of claim 115. Reference claim 16 corresponds to the limitations of claim 116. Reference claim 18 corresponds to the limitations of claim 117. Reference claims 19-23 corresponds to the limitations of claims 118-122, respectively. Reference claims 8-10 are drawn to a method of reducing or stopping blood loss at a location in a subject in need thereof corresponding to the limitations of claim 123-125.
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Reference claims 1-30 in a manner that arrives at the claimed invention. One of ordinary skill in the art would have been motivated to combine Reference claims 1-30 with a reasonable expectation of success because Reference Claim 13 recites the hemostatic hydrogel wherein, when formed with a thickness of 2 mm to 10 mm, providing guidance for selecting the hydrogel composition including this feature from within the scope of Reference claims 1-12 and 14-30.
Regarding claim 106 reciting a “biodegradable” hydrogel composition, MPEP 2112.01 especially at I. citing In re Best, 562 F.2d 1252, 195 USPQ 430 (C.C.P.A. 1977) and In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) discusses the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly recited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to show the products of the applicant and the prior art are not the same or that the prior art products do not necessarily possess the characteristics of the claimed product. Both the hydrogel compositions of the Reference claims and the claimed hydrogel compositions comprise identical chemical components characterized by identical physical properties. Therefore there is reason to believe that the claimed inventions are drawn to identical subject matter, and the functions of being “hemostatic” and “biodegradable” are necessarily present in both claimed inventions.
Claims 106-114 and 116-125 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 10,517,988.
Although the claims at issue are not identical, they are not patentably distinct from each other because Reference claims 1-2, 5-6, and 13-30 are drawn to a hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an acetic acid solution prior to acrylation, addressing limitations of claim 116. Reference claim 1 recites the hydrogel composition having one or more features including the alternative (xvi) substantially transparent when the hydrogel composition has a thickness of 2 mm to 10 mm, addressing limitations of claim 106. Reference claim 1 recites the hydrogel composition having one or more features including the alternatives (ix), (x), and (iv), addressing limitations of claims 107-109, respectively. Reference claim 2 recites the hydrogel composition comprising specific mole fractions of formulas (I), (III), and (V), addressing limitations of claim 110. Reference claim 16 recites specific mole fractions of formula (IV), addressing limitations of claim 111. Reference claim 17 recites specific mole fractions of formula (VIII), addressing limitations of claim 112. Reference claim 1 recites the hydrogel composition having one or more features including the alternatives (xiv) and (xv), addressing limitations of claims 113-114, respectively. Reference claim 6 corresponds to the limitations of claim 117. Reference claims 13-17 corresponds to the limitations of claims 118-122, respectively. Reference claims 7-12 are drawn to a method of reducing or stopping blood loss at a location in a subject in need thereof, where reference claim 7 and alternatives listed in reference claim 8 corresponding to the limitations of claim 123-125. Reference claims 3-4 are drawn to a method of preparing the hemostatic hydrogel composition of the reference claims, and make obvious possession of the hemostatic hydrogel composition prepared thereby.
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Reference claims 1-30 in a manner that arrives at the claimed invention. One of ordinary skill in the art would have been motivated to combine Reference claims 1-30 with a reasonable expectation of success because Reference claim 1 recites the hydrogel composition having one or more features including the alternative (xvi), providing guidance for selecting the hydrogel composition including this feature from within the scope of Reference claims 1-30.
Regarding claim 106 reciting a “biodegradable” hydrogel composition, MPEP 2112.01 especially at I. citing In re Best, 562 F.2d 1252, 195 USPQ 430 (C.C.P.A. 1977) and In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) discusses the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly recited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to show the products of the applicant and the prior art are not the same or that the prior art products do not necessarily possess the characteristics of the claimed product. Both the hydrogel compositions of the Reference claims and the claimed hydrogel compositions comprise identical chemical components characterized by identical physical properties. Therefore there is reason to believe that the claimed inventions are drawn to identical subject matter, and the functions of being “hemostatic” and “biodegradable” are necessarily present in both claimed inventions.
Claims 106-113 and 116-125 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 11,033,654.
Although the claims at issue are not identical, they are not patentably distinct from each other because Reference claims 1-25 are drawn to a hemostatic hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an acetic acid solution prior to acrylation, addressing limitations of claim 116. Reference claim 16 recites the hemostatic hydrogel composition is substantially transparent when the hydrogel composition has a thickness of 2 mm to 10 mm, addressing limitations of claim 106. Reference claims 10-12 recites limitations corresponding to claims 107-109, respectively. Reference claim 19 recites the hydrogel composition comprising specific mole fractions of formulas (I), (III), and (V), addressing limitations of claim 110. Reference claim 23 recites specific mole fractions of formula (IV), addressing limitations of claim 111. Reference claim 24 recites specific mole fractions of formula (VIII), addressing limitations of claim 112. Reference claims 15 recites limitations corresponding to limitations of claim 113. Reference claim 18 corresponds to the limitations of claim 117. Reference claims 20-24 corresponds to the limitations of claims 118-122, respectively. Reference claims 28-32 are drawn to a method of reducing or stopping blood loss at a location in a subject in need thereof, where reference claim 28 and alternatives listed in reference claim 29 corresponding to the limitations of claim 123-125. Reference claims 26-27 are drawn to a method of preparing the hemostatic hydrogel composition of the reference claims, and make obvious possession of the hemostatic hydrogel composition prepared thereby.
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Reference claims 1-30 in a manner that arrives at the claimed invention. One of ordinary skill in the art would have been motivated to combine Reference claims 1-30 with a reasonable expectation of success because Reference claim 16 recites the hemostatic hydrogel composition is substantially transparent when the hydrogel composition has a thickness of 2 mm to 10 mm, providing guidance for selecting the hydrogel composition including this feature from within the scope of Reference claims 1-30.
Regarding claim 106 reciting a “biodegradable” hydrogel composition, MPEP 2112.01 especially at I. citing In re Best, 562 F.2d 1252, 195 USPQ 430 (C.C.P.A. 1977) and In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) discusses the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly recited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to show the products of the applicant and the prior art are not the same or that the prior art products do not necessarily possess the characteristics of the claimed product. Both the hydrogel compositions of the Reference claims and the claimed hydrogel compositions comprise identical chemical components characterized by identical physical properties. Therefore there is reason to believe that the claimed inventions are drawn to identical subject matter, and the functions of being “hemostatic” and “biodegradable” are necessarily present in both claimed inventions.
Citation of Prior Art
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Abrahams et al. (US 2009/0010982, published 08 Jan 2009, cited in PTO-892) teaches a biocompatible adherent sheet for use in surgical and medical procedures for sealing the tissues of a living mammal. The biocompatible adherent sheet includes a carrier sheet including a biocompatible polymer and a modified chitosan evenly disposed on one or both sides of the carrier sheet (abstract). In one embodiment the carrier sheet includes the reaction product of an alkylated chitosan and an oxidized polysaccharide, wherein the alkylated chitosan includes an acrylated chitosan (page 1, paragraph 8). In one embodiment, the oxidized polysaccharide includes an oxidized dextran (page 1, paragraph 14). It is believed that the aldehyde groups of oxidized polysaccharides interact with the amino groups of an alkylated chitosan in such a way as to markedly increase the viscosity of the mixture and cause gelation (page 6, paragraph 76).
Abrahams et al. does not specifically teach a biodegradable hydrogel composition comprising a gel produced by combining oxidized dextran with an acrylated chitosan composition produced by dissolving chitosan in an organic acid solution prior to acrylation, the biodegradable composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after combination of the oxidized dextran with the acrylated chitosan composition and when formed with a thickness of 2 mm to 10 mm is substantially transparent (claim 106).
It would not have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the teachings of Abrahams et al. in a manner that arrives at the claimed invention. While Abrahams et al. teaches the aldehyde groups of oxidized polysaccharides interact with the amino groups of an alkylated chitosan in such a way that causes gelation, Abrahams et al. does not provide guidance for selecting a biodegradable hydrogel composition comprising a burst strength of greater than about 70 mmHg as determined using an ASTM F 2392-04 protocol at about 5 minutes after combination of the oxidized dextran with the acrylated chitosan composition, or the composition when formed with a thickness of 2 mm to 10 mm is substantially transparent. Therefore the teachings of Abrahams et al. in view of the level of ordinary skill in the art does not teach or fairly suggest each and every limitation of the claimed invention.
Conclusion
No claim is currently in condition for allowance.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan S Lau whose telephone number is (571)270-3531. The examiner can normally be reached Monday-Friday 9a-5p Eastern.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at (571)270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JONATHAN S LAU/ Primary Examiner, Art Unit 1693